Skip to main content

Table 1 Clinicopathologic features of NK/T-cell lymphoma patients with aberrant expression of CD20 in present and previous literature review

From: Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review

No.

Author (yr.)

Age/Gender

(Ethnicity)

Primary site

Immunophenotype

BCR/TCR

Treatment

Follow-up

(months)

1

Present study

30/F

(Chinese)

Breast,stomach

CD20+++, CD3 + , CD4 + , CD56+++, TIA-1+, EBER(+), Ki67(90%)

+/+

CT (SMILE)

11,Alive

2

Huang,et al.

(2020)

67/M

(Chinese)

Testis

CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(90%)

+/−

Or + CT (P-GEMOX)

4, Alive

3

Huang,et al.

(2020)

41/F

(Chinese)

Nasal cavity

CD20 + , CD3 + , CD56 + , TIA-1+,Gran B+, Perforin+, EBER(+),Ki67(70%)

NA/NA

CT (EPOCH)

NA

4

Huang,et al.

(2020)

37/F

(Chinese)

Skin

CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(60%)

−/−

CT (P-GEMOX)

9,DOD

5

Huang,et al.

(2020)

62/M

(Chinese)

Nasal cavity

CD20 + , CD3 + , CD2 + , CD7p + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(60%)

NA/NA

CT (AspaMetDex + P-GEMOX)

18,DOD

6

Huang,et al.

(2020)

79/M

(Chinese)

Testis

CD20 + , CD3 + , CD2p + , TIA-1+, EBER(+), Ki67(80%)

−/−

Or

0.5,DOD

7

Huang,et al.

(2020)

67/M

(Chinese)

Nasal cavity

CD20 + , CD3 + , CD7 + , CD56 + , TIA-1+,Gran B+, EBER(+),Ki67(80%)

−/−

CT (P-GEMOX)

4,Alive

8

Huang,et al.

(2020)

29/M

(Chinese)

Skin,scrotum

CD20 + , CD3 + , CD2 + , CD56+ TIA-1+,Gran B+, Perforin+, EBER(+),Ki67(80%)

−/−

CT(P-GEMOX +GVD+

Pembrolizumab+PDL1+

Benzamine +Daratumumab +PD-1)

39,Alive

9

Huang,et al.

(2020)

37/M

(Chinese)

Testis

CD20 + , CD3 + , CD7 + , CD56 + , CD79a F+, TIA-1+, EBER(+),Ki67(75%)

NA/NA

Or + CT (Not specific)

NA

10

Huang,et al.

(2020)

60/M

(Chinese)

Soft tissue, LN

Nasal cavity,

scrotum

CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(60%)

−/−

CT (Not specific)

2,Alive

11

Huang,et al.

(2020)

56/M

(Chinese)

Skin

CD20 + , CD3 + , CD2 + , CD7 + , CD56 + , TIA-1+,Gran B+, Perforin+,EBER(+),Ki67(50%)

−/−

CT (GEMOX-L)

2, Alive

12

Huang,et al.

(2020)

81/M

(Chinese)

Nasal cavity, scrotum

CD20 + , CD3 + , CD7 + , CD56 + , TIA-1+, EBER(+), Ki67(90%)

NA/NA

CT (P-GEMOX)

3, Alive

13

Li D,et al.

(2017)

27/M

(Chinese)

Left cerebellum

CD20 + , CD3 + , CD2 + , Gran B+, EBER(+),Ki67(85%)

+/−

RT + steroid therapy

3,DOD

14

Huang YH,et al.

(2015)

48/M

(Taiwancsc)

Stomach

CD20 + , CD3+, CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(90%)

NA/−

C T (V I P, S M I L E)

8,DOD

15

Tsai YC,et al.

(2015)

32/M

(Taiwancsc)

Leg, back, LN

CD20 + , CD3 + , CD2 F + , CD56 + , TIA-1+,EBER(+)

NA/NA

CT (DICE)

6,Alive

16

Jiang QP,et al.

(2012)

78/F

(Chinese)

Nasal cavity

CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+), Ki67(60%)

−/−

Observation without treatment

6,Alive

17

Gill HS,et al.

(2010)

25/M

(Chinese)

Chest wall

CD20+, CD2 + , CD56 + , TIA-1+, EBER(+),Ki67(90%)

−/−

NA

NA

18

Kobold S,et al.

(2009)

69/M

(Caucasian)

Stomach

CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, Perforin+,

−/−

CT (CHOP)

1,DOD

19

Ando J,et al.

(2008)

71/M

(Japanese)

Thenar

CD20 + , CD3 + , CD2 + , CD56 + , TIA-1+,Gran B+, EBER(+)

−/−

CT (CHOP, ESHAP, and L-asparaginase)

6,DOD

  1. M male, F female, DOD die of disease, Or orchiectomy, CT chemotherapy, SMILE dexamethasone,methotrexate, ifosfamidpegaspargase, and etoposide, P-GEMOX pegaspargase, gemcitabine and oxaliplatin, GVD gemcitabine, doxorubicin liposomes and vinorelbine, GEMOX-L gemcitabine and oxaliplatin and L-asparaginase, EPOCH VP-16, epirubicin/adriamycin, vincristine, cyclophosphamide, and prednisone, AspaMetDex pegaspargase, methotrexate, and dexamethasone, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, ESHAP etoposide, methylprednisolone, cytarabine, cisplatin, DICE dexamethasone, etoposide, ifosfamide, and cisplatin, RT radiotherapy. VIP VP-16, ifosfamide, and cisplatin;